US$3 Million Strategic Investment in IGC Pharma

In March 2024, Bradbury completed a strategic investment in clinical-stage pharmaceutical company IGC Pharma, Inc. (NYSE American: IGC). The transaction was structured as an unregistered private placement of common stock, yielding gross proceeds of US$3 million to the issuer.

Capital from this placement is explicitly directed toward the advancement of the issuer's clinical research pipeline. This includes providing funding for the ongoing investigational trials of IGC-AD1, a therapeutic candidate targeting agitation in Alzheimer's disease, alongside standard corporate working capital.

The transaction reflects Bradbury's continued deployment of capital into regulated, clinical-stage life science mandates.